Table 1 Studies that have investigated the role of IL-17 family members and IL-23 in sepsis
From: Therapeutic potential of targeting IL-17 and IL-23 in sepsis
Reference | Species | Experimental Design | Main Results |
|---|---|---|---|
[26] | M. musculus | B. fragilis challenge | Neutralization of IL-17A prevented abscess formation. |
[23] | H. sapiens | Expression analysis in peripheral blood | Elevation of IL-23(p19) mRNA during sepsis. |
[27] | M. musculus | E. coli challenge | Neutralization of IL-17A impaired peritoneal clearance of E. coli. |
[8] | M. musculus | CLP | Neutralization of IL-17A reduced mortality. |
[22] | M. musculus | P. aeruginosa challenge | Neutralization of IL-23(p19) reduced mortality. |
[28] | M. musculus | CLP | Production of IL-6, MIP-1α, MIP-2 by cardiomyocytes required endogenous IL-17A. |
[6] | M. musculus | Endotoxemia | Neutralization of IL-17A or IL-23(p19) improved survival. Regulation of IL-17A and IL-23(p19) by C5a. |
[9] | M. musculus | Endotoxemia, CLP | C5a dependency of production of IL-17 F. |
[25] | H. sapiens (premature infants) | Monocytes, DCs | Defect in the production of IL-12/IL-23 p40 in premature infants. |